Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Margarita Amenedo

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Archivos Espanoles De Urologia|October 14, 2014
Choriocarcinoma syndromeAna Medina, Manuel Ramos, Margarita Amenedo, et al.
Investigational New Drugs|August 5, 2004
Docetaxel plus fractionated cisplatin is a safe and active schedule as first-line treatment of patients with advanced non-small cell lung cancer: results of a phase II studyJosé Luis Firvida, Margarita Amenedo, Rubén Rodríguez, et al.
Anti-Cancer Drugs|January 4, 2014
Second-line treatment in advanced non-small-cell lung cancer in the epidermal growth factor receptor wild-type population: review of patient profileSergio Vázquez, Martín Lázaro, José Luis Fírvida, et al.
Expert Opinion on Pharmacotherapy|May 29, 2012
First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patientsLuis Leon, Sergio Vázquez, José Manuel Gracia, et al.
Anti-Cancer Drugs|May 29, 2004
Biweekly docetaxel as second-line chemotherapy of patients with advanced non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 006-00)Sergio Vázquez, Carlos Grande, Margarita Amenedo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2004
Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III studyEmilio Alba, Miguel Martín, Manuel Ramos, et al.
Anti-Cancer Drugs|September 26, 2007
Biweekly administration of docetaxel and vinorelbine as second-line chemotherapy for patients with stage IIIB and IV non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 013-02)Sergio Vázquez, Gerardo Huidobro, Margarita Amenedo, et al.
Cancer Chemotherapy and Pharmacology|February 3, 2007
Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II studyJoaquín Casal, Margarita Amenedo, José Ramón Mel, et al.
Cancer Management and Research|February 20, 2016
EGFR testing and clinical management of advanced NSCLC: a Galician Lung Cancer Group study (GGCP 048-10)Sergio Vázquez, Joaquín Casal, Francisco Javier Afonso Afonso, et al.
Translational Lung Cancer Research|February 4, 2020
Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapyJuan Ruiz-Bañobre, María C Areses-Manrique, Joaquín Mosquera-Martínez, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Archivos Espanoles De Urologia|October 14, 2014
Choriocarcinoma syndromeAna Medina, Manuel Ramos, Margarita Amenedo, et al.
Investigational New Drugs|August 5, 2004
Docetaxel plus fractionated cisplatin is a safe and active schedule as first-line treatment of patients with advanced non-small cell lung cancer: results of a phase II studyJosé Luis Firvida, Margarita Amenedo, Rubén Rodríguez, et al.
Anti-Cancer Drugs|January 4, 2014
Second-line treatment in advanced non-small-cell lung cancer in the epidermal growth factor receptor wild-type population: review of patient profileSergio Vázquez, Martín Lázaro, José Luis Fírvida, et al.
Expert Opinion on Pharmacotherapy|May 29, 2012
First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patientsLuis Leon, Sergio Vázquez, José Manuel Gracia, et al.
Anti-Cancer Drugs|May 29, 2004
Biweekly docetaxel as second-line chemotherapy of patients with advanced non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 006-00)Sergio Vázquez, Carlos Grande, Margarita Amenedo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2004
Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III studyEmilio Alba, Miguel Martín, Manuel Ramos, et al.
Anti-Cancer Drugs|September 26, 2007
Biweekly administration of docetaxel and vinorelbine as second-line chemotherapy for patients with stage IIIB and IV non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 013-02)Sergio Vázquez, Gerardo Huidobro, Margarita Amenedo, et al.
Cancer Chemotherapy and Pharmacology|February 3, 2007
Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II studyJoaquín Casal, Margarita Amenedo, José Ramón Mel, et al.
Cancer Management and Research|February 20, 2016
EGFR testing and clinical management of advanced NSCLC: a Galician Lung Cancer Group study (GGCP 048-10)Sergio Vázquez, Joaquín Casal, Francisco Javier Afonso Afonso, et al.
Translational Lung Cancer Research|February 4, 2020
Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapyJuan Ruiz-Bañobre, María C Areses-Manrique, Joaquín Mosquera-Martínez, et al.
Pageof 3